Pharmala Biotech Holdings Inc.
Pharmala Biotech Holdings Inc.
Share · CA71719L1067 (XCNQ)
Overview
No Price
Closing Price XCNQ 27.10.2025: 0,11 CAD
27.10.2025 19:56
Current Prices from Pharmala Biotech Holdings Inc.
ExchangeTickerCurrencyLast TradePriceDaily Change
XCNQ: CSE LISTED
CSE LISTED
MDMA.CN
CAD
27.10.2025 19:56
0,11 CAD
0,005 CAD
+4,76 %
Share Float & Liquidity
Free Float 90,56 %
Shares Float 95,71 M
Shares Outstanding 105,68 M
Company Profile for Pharmala Biotech Holdings Inc. Share
Pharmala Biotech Holdings Inc., doing business as PharmAla, focuses on the developing, manufacturing, and commercializing of substituted methylenedioxy-phenethylamines (MDXX) active pharmaceutical ingredients. It also provides MDXX class compounds, such as 1,3-Benzodioxolyl-Nmethylbutanamine (MBDB); and 3,4-Methylenedioxy-N-ethylamphetamine (MDEA/MDE), as well as formulations of MDXX compounds. The company is headquartered in Vancouver, Canada.
Get up to date insights from finAgent about Pharmala Biotech Holdings Inc.

Company Data

Name Pharmala Biotech Holdings Inc.
Company Pharmala Biotech Holdings Inc.
Website https://pharmala.ca
Primary Exchange XCNQ CSE LISTED
ISIN CA71719L1067
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Nicholas Kadysh
Market Capitalization 14 Mio
Country Canada
Currency CAD
Employees -
Address 1111 Melville Street, V6E 3V6 Vancouver
IPO Date 2022-01-11

Ticker Symbols

Name Symbol
CSE LISTED MDMA.CN
More Shares
Investors who hold Pharmala Biotech Holdings Inc. also have the following shares in their portfolio:
EURONEXT 21/31
EURONEXT 21/31 Bond
SCHLW-H.SCHATZ.18/23 A1
SCHLW-H.SCHATZ.18/23 A1 Bond
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025